Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Thiazinoquinones as new promising multi-stage schistosomicidal compounds impacting Schistosoma mansoni and egg viability.

Gimmelli R, Persico M, Imperatore C, Saccoccia F, Guidi A, Casertano M, Luciano P, Pietrantoni A, Bertuccini L, Paladino A, Papoff G, Menna M, Fattorusso C, Ruberti G.

ACS Infect Dis. 2019 Nov 13. doi: 10.1021/acsinfecdis.9b00252. [Epub ahead of print]

PMID:
31718145
2.

Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) Inhibitors as Multistage Antischistosomal Agents.

Saccoccia F, Brindisi M, Gimmelli R, Relitti N, Guidi A, Saraswati AP, Cavella C, Brogi S, Chemi G, Butini S, Papoff G, Senger J, Herp D, Jung M, Campiani G, Gemma S, Ruberti G.

ACS Infect Dis. 2019 Nov 12. doi: 10.1021/acsinfecdis.9b00224. [Epub ahead of print]

PMID:
31661956
3.

Identification of novel multi-stage histone deacetylase (HDAC) inhibitors that impair Schistosoma mansoni viability and egg production.

Guidi A, Saccoccia F, Gennari N, Gimmelli R, Nizi E, Lalli C, Paonessa G, Papoff G, Bresciani A, Ruberti G.

Parasit Vectors. 2018 Dec 27;11(1):668. doi: 10.1186/s13071-018-3268-8.

4.

CASP4 gene silencing in epithelial cancer cells leads to impairment of cell migration, cell-matrix adhesion and tissue invasion.

Papoff G, Presutti D, Lalli C, Bolasco G, Santini S, Manelfi C, Fustaino V, Alemà S, Ruberti G.

Sci Rep. 2018 Dec 7;8(1):17705. doi: 10.1038/s41598-018-35792-8.

5.

Tis21-gene therapy inhibits medulloblastoma growth in a murine allograft model.

Presutti D, Ceccarelli M, Micheli L, Papoff G, Santini S, Samperna S, Lalli C, Zentilin L, Ruberti G, Tirone F.

PLoS One. 2018 Mar 14;13(3):e0194206. doi: 10.1371/journal.pone.0194206. eCollection 2018.

6.

Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines.

Fustaino V, Presutti D, Colombo T, Cardinali B, Papoff G, Brandi R, Bertolazzi P, Felici G, Ruberti G.

Oncotarget. 2017 Sep 22;8(61):103340-103363. doi: 10.18632/oncotarget.21132. eCollection 2017 Nov 28.

7.

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.

Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G.

PLoS One. 2015 Nov 18;10(11):e0143333. doi: 10.1371/journal.pone.0143333. eCollection 2015.

8.

N-terminal and C-terminal domains of calmodulin mediate FADD and TRADD interaction.

Papoff G, Trivieri N, Marsilio S, Crielesi R, Lalli C, Castellani L, Balog EM, Ruberti G.

PLoS One. 2015 Feb 2;10(2):e0116251. doi: 10.1371/journal.pone.0116251. eCollection 2015.

9.

FADD-calmodulin interaction: a novel player in cell cycle regulation.

Papoff G, Trivieri N, Crielesi R, Ruberti F, Marsilio S, Ruberti G.

Biochim Biophys Acta. 2010 Aug;1803(8):898-911. doi: 10.1016/j.bbamcr.2010.04.006. Epub 2010 Apr 24.

10.

Resistance to gemcitabine in a lymphoma cell line resistant to Fas-mediated apoptosis.

Meli M, Tolomeo M, D'Alessandro N, Grimaudo S, Notarbartolo M, Papoff G, Ruberti G, Rausa L, Dusonchet L.

Anticancer Res. 2004 Mar-Apr;24(2B):851-7.

11.

Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor.

Papoff G, Hausler P, Eramo A, Pagano MG, Di Leve G, Signore A, Ruberti G.

J Biol Chem. 1999 Dec 31;274(53):38241-50.

12.

The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.

Tolomeo M, Dusonchet L, Meli M, Grimaudo S, D'Alessandro N, Papoff G, Ruberti G, Rausa L.

Cell Death Differ. 1998 Sep;5(9):735-42.

13.
14.

Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B.

Häusler P, Papoff G, Eramo A, Reif K, Cantrell DA, Ruberti G.

Eur J Immunol. 1998 Jan;28(1):57-69.

15.

Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome.

Baiocchi RA, Khatri VP, Lindemann MJ, Ross ME, Papoff G, Caprio AJ, Caprio TV, Fenstermaker R, Ruberti G, Bernstein ZP, Caligiuri MA.

Blood. 1997 Sep 1;90(5):1737-46.

PMID:
9292506
16.

Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis.

Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A.

Science. 1997 Feb 14;275(5302):960-3.

17.

An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro.

Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G.

J Immunol. 1996 Jun 15;156(12):4622-30.

PMID:
8648105
18.

Soluble Fas/Apo-1 splicing variants and apoptosis.

Cascino I, Papoff G, Eramo A, Ruberti G.

Front Biosci. 1996 Jan 1;1:d12-8. Review.

PMID:
9159204
19.

Fas splicing variants and their effect on apoptosis.

Ruberti G, Cascino I, Papoff G, Eramo A.

Adv Exp Med Biol. 1996;406:125-34. Review. No abstract available.

PMID:
8910678
20.

Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis.

Cascino I, Papoff G, De Maria R, Testi R, Ruberti G.

J Immunol. 1996 Jan 1;156(1):13-7.

PMID:
8598453
21.

Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing.

Cascino I, Fiucci G, Papoff G, Ruberti G.

J Immunol. 1995 Mar 15;154(6):2706-13.

PMID:
7533181

Supplemental Content

Loading ...
Support Center